Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179436 | 1.00 | HTR1A (0.43) | HTR1ADRD2KDM1AL3MBTL1LMNA | |
| SCHEMBL20179475 | 1.00 | HTR1A (0.43) | HTR1ADRD2KDM1AL3MBTL1LMNA | |
| SCHEMBL19988037 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAFFAR4 | |
| SCHEMBL19988040 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAFFAR4 | |
| SCHEMBL19988032 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAFFAR4 | |
| SCHEMBL19988048 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAFFAR4 | |
| SCHEMBL19988033 | 0.81 | HTR1A (0.43) | HTR1ADRD2L3MBTL1LMNAFFAR4 | |
| SCHEMBL18894534 | 0.81 | HTR1A (0.53) | HTR1ADRD2L3MBTL1LMNAFFAR4 | |
| SCHEMBL23940700 | 0.80 | SLC6A2 (0.45) | HTR1ADRD2KDM1AL3MBTL1LMNA | |
| SCHEMBL20006884 | 0.80 | SLC6A2 (0.45) | HTR1ADRD2KDM1AL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | HTR1A 1318/4885DRD2 205/4885KDM1A 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.